Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter

Cancer

Volumn 82, Issue 2, 1998, Pages 334-341

  D'Amico, Anthony V ^a   Whittington, Richard ^b   Kaplan, Irving ^a   Beard, Clair ^a   Schultz, Delray ^c   Malkowicz, S Bruce ^b   Wein, Alan ^b   Tomaszewski, John E ^b   Coleman, C Norman ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Millersville   (United States)

Author keywords

Cancer volume; Prognostic factor; Prostate carcinoma; Prostate specific antigen; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; RADIATION DOSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; FORECASTING; HUMANS; LYMPH NODE EXCISION; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 0031974984     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980115)82:2<342::AID-CNCR14>3.0.CO;2-Z     Document Type: Article

References (27)

1. Beahrs OH, Henson DE, Hutter RVP. American Joint Committee on Cancer. Manual for staging of cancer. 4th edition. Philadelphia: J. B. Lippincott, 1992.
2. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer 1996;77:2162-6.
3. Oesterling JE, Suman VJ, Zincke H, Bostwick D. PSA detected (clinical stage T1c or B0) prostate cancer. Urol Clin North Am 1993;20:687-93.
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
5. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-21.
6. Carter HB, Pearson JL, Metter J, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
7. Partin AW, Yoo J, Ballentine Carter H, Pearson JD, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage, and gleason score to predict pathologic stage in men with prostate cancer. J Urol 1993;150:110-4.
8. Roach M, Marquez C, Yuo H-S, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1993;28:33-7.
9. D'Amico AV, Propert K. Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 1996;35:273-9.
10. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
11. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer 1997;79:337-44.
12. D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski JE, Schultz D, et al. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol. 1997;158:1422-6.
13. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Pironen T, Abrahamsson P, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
14. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-99.
15. D'Amico AV, Chang H, Holoupka E, Renshaw A, Desjarden A, Chen M, et al. Calculated prostate cancer volume: the optimal predictor of the actual prostate cancer volume. Urology 1997;49:385-91.
16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-500.
17. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external beam radiotherapy alone: serum prostate specific antigen driven outcome analysis. J Clin Oncol 1995;13:464-9.
18. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, et al. Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993; 11:2158-66.
19. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
20. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-9.
21. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-8.
22. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H. Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137-43.
23. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994;43:828-33.
24. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. PSA failure despite pathologically organ confined and margin negative disease: the basis for an adjuvant therapy trial. J Clin Oncol 1997;15:1465-9.
25. Lankford SP, Pollack A, Zagars GK. Prostate specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Int J Radiat Oncol Biol Phys, 1997:38:327-334.
26. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, et al. Dose escalation in the conformal treatment of prostate cancer: optimization is made possible by understanding the dose response for control of cancer and late morbidity. Int J Radiat Oncol Biol Phys 1996;36(Suppl 1):197.
27. Pilepich MV, Krall JM, Al-Sarraf M, Scotte-Doggett RL, Sause WT, Lawton CA, et al. Androgen deprivation with radiation compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-22.